Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1283526 | 1.00 | CYP2D6 (0.47) | CYP2D6MAPTHTTCCR2KCNH2 | |
| SCHEMBL1283776 | 1.00 | CYP2D6 (0.47) | CYP2D6MAPTHTTCCR2KCNH2 | |
| SCHEMBL14155736 | 0.87 | — | — | |
| SCHEMBL17311068 | 0.87 | — | — | |
| SCHEMBL4099948 | 0.87 | — | — | |
| SCHEMBL5066037 | 0.84 | DRD3 (0.47) | CYP2D6 | |
| SCHEMBL4377471 | 0.84 | HSD11B1 (0.39) | CYP2D6MAPTCCR2KCNH2HSD11B1 | |
| SCHEMBL28250446 | 0.84 | HSD11B1 (0.39) | CYP2D6MAPTCCR2KCNH2HSD11B1 | |
| SCHEMBL25147628 | 0.83 | CYP2D6 (0.50) | CYP2D6MAPTHTTLTA4HNPC1 | |
| SCHEMBL12718219 | 0.83 | BCHE (0.40) | CYP2D6CCR2KCNH2HSD11B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116444750-A | Foaming polyurethane or polyurea water dispersion, preparation method and application | 万华化学集团股份有限公司 | 2023-07-18 | — | — | CN | claimed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | claimed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | claimed |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | claimed |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | claimed |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | claimed |
| US-9695168-B2 | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | claimed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | claimed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | claimed |
| WO-2016007731-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | claimed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | claimed |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | claimed |
| EP-4712950-A2 | IONIZABLE AMINE LIPIDS | Intellia Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260001838-A1 | NANOMATERIALS | GUIDE THERAPEUTICS LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250387509-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | BEAM THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12435035-B2 | Nanomaterials | GUIDE THERAPEUTICS, LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-5324737-A | Analgesics, antirheumatic and antiinflammatory agents, glaucoma | STERLING WINTHROP INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5068234-A | Analgesics, rheumatic diseases, antiinflammatory agents or antiglaucoma | STERLING DRUG INC. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0444451-A2 | 3-Arylcarbonyl-1H-indoles useful as therapeutic agents | STERLING WINTHROP INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-3983245-A | CORONARY VASODILATORS | SMITHKLINE CORPORATION (US) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM2A, KDM1A | CYP2D6 868/4885MAPT 2661/4885HTT 3360/4885 |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CYP2D6 934/4885MAPT 2926/4885HTT 4056/4885 |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CYP2D6 934/4885MAPT 2926/4885HTT 4056/4885 |
| US-20260001838-A1 | NANOMATERIALS | SLC10A1, NPC1L1, FABP1 | CYP2D6 996/4885MAPT 2637/4885HTT 1895/4885 |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CYP2D6 938/4885MAPT 2883/4885HTT 3524/4885 |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM2A, KDM1A | CYP2D6 868/4885MAPT 2661/4885HTT 3360/4885 |
| US-12435035-B2 | Nanomaterials | NPC1, NPC1L1, FABP1 | CYP2D6 3101/4885MAPT 2908/4885HTT 2131/4885 |
| US-20250387509-A1 | NANOMATERIALS COMPRISING A BIODEGRADABLE FEATURE | LDLR, TGFBR2, MSR1 | CYP2D6 34/4885MAPT 1712/4885HTT 3335/4885 |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | KDM5A, KDM1A, KDM1B | CYP2D6 934/4885MAPT 2926/4885HTT 4056/4885 |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM5A | CYP2D6 995/4885MAPT 1962/4885HTT 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.